Improving cancer drugs based on ADCs

Collaboration with: Chromacon (Switzerland)
Funded by: Eurostars
Time period : 2015-2018

This project has led to an improvement of ChromaCon’s MCSGP technology for purification of ADC’s. It also improved Alphalyse’s analytical methods for detailed antibody drug conjugates characterization and their drug-antibody-ratios (DAR). The developed analytical tools are beneficial for ChromaCon as well as other biopharmaceutical companies developing ADC’s and monoclonal antibodies (mAbs).

Antibody drug conjugates (ADCs) are site-directed monoclonal antibodies (mAbs) coupled to highly potent cytotoxins with great potential for targeted treatment of various types of cancer. The drug-antibody-ratio (DAR) is important for the dosing, but difficult to control in manufacturing and analytical characterization.

Study design used to evaluate Chromacon’s ADC purification

The analysis method for antibody drug conjugates characterization includes DAR profiling. UV LC-MS/MS determines the MW of the intact ADC, and of ADC subunits generated by IdeS cleavage.

The Eurostars project was a co-development between Alphalyse and ChromaCon. The two teams worked on ADC purification technologies and analytical methods for antibody-drug conjugates (ADCs).

Talk with our experts

  • This field is for validation purposes and should be left unchanged.
Improve your protein research
Subscribe to our newsletter and get 3 tips that will instantly improve your protein analysis results

Receive monthly emails with news, tips, case stories
and offers for protein analysis
© Copyright Alphalyse 2002 - 2023. All rights reserved.